-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals only
Summarizing the process of disease development is extremely complex and does not exist independently, and multiple diseases
are often combined in the same patient.
In such complex cases, treatment should be treated with particular caution and efficacy and safety should not be abandoned
.
Rheumatism, tumours and infections are closely related and often affect
each other.
In AS therapy, patients with a tumor or previous tumor history, or who are at risk of tuberculosis/hepatitis B infection, choose a higher-safety, lower-risk scuciumab or an ideal treatment option
.
Evidence suggests that the low incidence of adverse events such as tuberculosis/hepatitis B relapse or malignancy during the treatment of AS by scuciliumab ensures drug safety
while exerting significant efficacy.
References
MCC number CXA22091862 is valid for 2023-09-21, and the information is expired and deemed invalid
.
IL-17A inhibitors or AS co-existing tumor patients are preferred for
treatment.
Summarizing the process of disease development is extremely complex and does not exist independently, and multiple diseases
are often combined in the same patient.
In such complex cases, treatment should be treated with particular caution and efficacy and safety should not be abandoned
.
Rheumatism, tumours and infections are closely related and often affect
each other.
In AS therapy, patients with a tumor or previous tumor history, or who are at risk of tuberculosis/hepatitis B infection, choose a higher-safety, lower-risk scuciumab or an ideal treatment option
.
Evidence suggests that the low incidence of adverse events such as tuberculosis/hepatitis B relapse or malignancy during the treatment of AS by scuciliumab ensures drug safety
while exerting significant efficacy.
References
[1] Chang CC, et al.
Oncol Lett.
2017, 14(2):1315-1322.
[2]Deng C, et al.
Sci Rep.
2016, 6:32063.
[3]Chan TM, et al.
Scand J Rheumatol.
2021, 50(2):132-138.
[4]Blair HA.
Drugs.
2019, 79(4):433-443.
[5]Zhao J, et al.
J Exp Med.
2020, 217(1): e20190297.
[6]Kuen DS, et al.
Immune Netw.
2020, 20(1):e6.
[7]Vitiello GA, et al.
J Exp Med.
2020, 217(1):e20190456.
[8]Gottlieb AB, et al.
Acta Derm Venereol.
2022, 102:adv00698.
[9]Wadström H, et al.
JAMA Intern Med.
2017, 177(11):1605-1612.
[10]Kim SC, et al.
Arthritis Rheumatol.
2016, 68(9):2106-13.
[11] Joint Surgery Committee of Chinese Society of Research Hospitals.
Chinese Journal of Joint Surgery (Electronic Edition).
2019, 13(3):261-266.
[12]Rasheed RA, et al.
International Journal of Health Sciences, 2022, 6(S8): 103-111.
[13]Deodhar, et al.
Arthritis Research & Therapy.
2019, 21:111.
[14]Boni E.
Elewski, et al.
2020 American Academy of Dermatology (AAD) Annual Meeting.
#15261.
MCC number CXA22091862 is valid for 2023-09-21, and the information is expired and deemed invalid
.
This article is for the sole purpose of providing scientific information to healthcare professionals and does not represent the position of the
Platform.
